Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences (NASDAQ: ANIX) reported updated survival and safety observations from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer.
Multiple patients have lived well beyond the typical three‑to‑four‑month median survival, and preliminary safety data show no dose‑limiting toxicities, ICANS or significant CRS in the first three dose cohorts.
Anixa Biosciences (NASDAQ: ANIX) reported updated survival and safety data from its ongoing Phase 1 trial of lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Multiple patients lived well beyond the typical 3–4 month median survival, with no dose-limiting toxicities, ICANS or significant CRS observed so far.
Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will be interviewed on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV Saturday, May 2, 2026 at 7pm ET. The interview will review the company, its capital‑efficient model, the breast cancer vaccine Phase 1 results showing protocol‑defined immune responses in 74% of participants, and ongoing positive survival data for ovarian CAR‑T therapy lira‑cel in a Phase 1 trial. Bloomberg TV reaches an estimated 73 million U.S. homes; the segment is also available online via Anixa’s website.
Anixa Biosciences (NASDAQ: ANIX) announced that the Mexican Institute of Industrial Property issued Patent No. 432748, covering key aspects of its breast cancer vaccine technology and extending IP protection in Mexico into the 2040s.
The vaccine, licensed from Cleveland Clinic and targeting human α-lactalbumin, showed Phase 1 safety and protocol-defined immune responses in 74% of participants; Anixa is preparing a Phase 2 clinical trial and highlights continued expansion of its global patent estate.
Anixa (NASDAQ: ANIX) announced a presentation on its ovarian cancer CAR-T therapy, lira-cel, at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, May 6–9, 2026.
The presentation will cover the Phase 1 trial design, objectives, and the current status, with the company noting that lira-cel continues to show positive survival data in the ongoing study.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Amit Kumar, chairman and CEO, will present at RedChip's virtual Biotech Resurgence conference on April 16, 2026 at 3:30 pm ET.
The presentation will review the company, its Phase 1 breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants, and ovarian CAR-T therapy lira-cel showing positive survival data in an ongoing Phase 1 trial. The session includes a live Q&A for investors and registration details.
Anixa Biosciences (NASDAQ: ANIX) announced Dr. Amit Kumar, chairman and CEO, will present at the Water Tower Research Insights Conference on April 14, 2026 at 12:30 pm ET. The virtual presentation will cover company strategy, clinical programs, and recent trial highlights.
Key clinical updates noted include a breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants in a Phase 1 trial, and ongoing Phase 1 ovarian CAR-T therapy lira-cel reporting positive survival data.
Anixa Biosciences (NASDAQ: ANIX) said its CEO Dr. Amit Kumar discussed the company’s advancing immunotherapy pipeline on Smart Money Circle on April 6, 2026. Key clinical updates: the breast cancer vaccine completed Phase 1 meeting primary endpoints with protocol-defined immune responses in 74% of participants, and the ovarian CAR-T therapy lira-cel is showing positive survival data in an ongoing Phase 1 trial.
The interview highlights clinical progress across both programs and ongoing development work for potential next steps.
Anixa Biosciences (NASDAQ: ANIX) reported positive final Phase 1 results for its α-lactalbumin breast cancer vaccine and has engaged Cytovance Biologics to produce cGMP clinical material for a planned Phase 2 trial.
The Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants.
Anixa (NASDAQ: ANIX) announced that Dr. Robert Wenham of Moffitt Cancer Center will present an update on the company’s Phase 1 ovarian cancer CAR-T trial (lira-cel) at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, April 10–13, 2026 in San Juan, Puerto Rico.
The presentation will cover the trial design, objectives, and current status of the autologous T-cell therapy targeting FSHR in recurrent ovarian cancer.